← Issue №18/ week of Nov 1, 2026/Motility

Gut relief revisited: plecanatide in chronic idiopathic constipation and irritable bowel syndrome with constipation - a systematic review and meta-analysis with GRADE assessment.

From GI Signals issue №18: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Motility meta analysis · Oct 26, 2026 · BMC Gastro · IF 2.5

Gut relief revisited: plecanatide in chronic idiopathic constipation and irritable bowel syndrome with constipation - a systematic review and meta-analysis with GRADE assessment.

New evidencechronic constipationIBSmeta-analysissystematic review
Clinical takeawayConsider plecanatide, particularly the 3 mg dose, for adults with chronic idiopathic constipation (CIC) or irritable bowel syndrome with constipation (IBS-C), balancing efficacy and safety, while monitoring for diarrhea, the most frequent adverse event.
What it foundPlecanatide significantly increased complete spontaneous bowel movements (CSBMs) by 0.75-1.00 across doses compared to placebo, with the greatest improvement at 9 mg, and improved spontaneous bowel movements (SBMs) by 0.97-1.58 at 1-6 mg.
ContextConfirms plecanatide's efficacy and safety in adults with CIC and IBS-C, refining dose selection with evidence supporting 3 mg as optimal, though diarrhea remains a dose-related concern.
Measured against the standard of care· AGA-ACG 2023 (Chang L et al., Am J Gastroenterol 2023;118:936-954, doi 10.14309/ajg.0000000000002227) / AGA Clinical Practice Update 2026 (Staller K et al., Clin Gastroenterol Hepatol 2026;24(2):296-305, doi 10.1016/j.cgh.2025.09.031, PMID 41504675) / ASCRS-ICS-IUGA-AUGS-APTA Pelvic Floor Consortium consensus 2026 (Traugott AL et al., Dis Colon Rectum 2026;69(3):346-359, doi 10.1097/DCR.0000000000003993)

First-line drug treatment for adults with chronic idiopathic constipation has not changed. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

First-line drug treatment for adults with chronic idiopathic constipation has not changed. It still follows the AGA-ACG 2023 GRADE guideline. STRONG recommendation (moderate certainty) for polyethylene glycol. STRONG recommendation (moderate certainty) for bisacodyl or sodium picosulfate, limited to short-term or rescue use. CONDITIONAL suggestion for fiber (low certainty), magnesium oxide (very low) and senna (low). For patients who do not respond to, fail, or cannot tolerate over-the-counter agents: STRONG recommendation (moderate certainty) for linaclotide, plecanatide and prucalopride, and CONDITIONAL suggestion for lubiprostone (low) and lactulose (very low). The guideline gives no doses, no required order and no fixed trial length; it uses shared decision making and leaves anorectal evacuation disorders to the ACG 2021 benign anorectal guideline. Added on top of this is the AGA 2026 Clinical Practice Update on refractory constipation (Staller, Neshatian, Lembo, Bharucha; expert-opinion Best Practice Advice, 14 key clinical issues, no formal evidence grading). Before calling constipation refractory, clinicians should systematically (1) exclude correctable secondary causes: medications, neurologic disorders, and defecatory disorders; (2) confirm slow colonic transit objectively, ideally both off therapy and on maximal therapy; and (3) make sure the patient has had adequate trials of over-the-counter and FDA-approved drugs and nonpharmacologic therapy, including combinations. Most patients should have anorectal testing and, when indicated, pelvic floor biofeedback before being labeled refractory. Colectomy can be considered only after all of these fail. Before surgery: confirm slow transit, exclude a concurrent defecatory disorder, evaluate for severe symptomatic delayed gastric emptying or small-bowel dysmotility, and do a psychological evaluation. Relative contraindications are clinically significant upper-gut dysmotility, severe untreated psychiatric disease, and bloating or abdominal pain as the main complaint. A temporary diverting loop ileostomy may predict response in uncertain cases. Colectomy with ileorectal anastomosis should be offered only to patients without an ongoing defecatory disorder. For obstructed defecation and posterior compartment or rectal prolapse, a 2026 consensus of the ASCRS Pelvic Floor Consortium with ICS, IUGA, AUGS and APTA (15 statements, >70% consensus, expert-consensus evidence) advises prompt referral to pelvic floor physical therapy for patients without contraindications. It also advises therapy individualized to the diagnostic evaluation and the patient's goals, deliberate timing of therapy relative to surgery, and trauma-informed care.

AGA-ACG 2023 (Chang L et al., Am J Gastroenterol 2023;118:936-954, doi 10.14309/ajg.0000000000002227) / AGA Clinical Practice Update 2026 (Staller K et al., Clin Gastroenterol Hepatol 2026;24(2):296-305, doi 10.1016/j.cgh.2025.09.031, PMID 41504675) / ASCRS-ICS-IUGA-AUGS-APTA Pelvic Floor Consortium consensus 2026 (Traugott AL et al., Dis Colon Rectum 2026;69(3):346-359, doi 10.1097/DCR.0000000000003993) · reviewed 2026-10-25 ↗
Aboelkhier MM … Alsayed AR · BMC Gastroenterology · IF 2.5 · PubMed ↗Permalink
← Read the whole of issue №18 Every paper GI Signals surfaces gets a page like this one. All issues